{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:09:52Z","timestamp":1792782592415,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Lund University","id":[{"id":"https:\/\/ror.org\/012a77v79","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>This study aims to characterize the antiproliferative and antitumor activity of NOV202, a novel vascular-disrupting and microtubule-destabilizing compound, alone and in combination withthe PARP inhibitor olaparib, in preclinical prostate cancer models in vitro and in vivo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>DU145 (carrying a BRCA2 variant of unknown significance) and PC-3 (BRCA2 wildtype) prostate cancer cells were implanted in NMRI nude mice. Mice received oral olaparib, NOV202, or both for 21 days. Tumor growth was monitored via bioluminescence imaging and caliper measurements. By immunohistochemistry we assessed DNA damage (\u03b3H2AX), homologous recombination repair (RAD51), hypoxia (HIF-1\u03b1), proliferation (Ki-67), vascularization (CD31) and apoptosis (cleaved caspase 3). Cell viability assays and western blot analyses were performed to assess treatment-induced DNA-damage and apoptosis markers and to evaluate synergistic effects in vitro.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Olaparib and NOV202 independently reduced tumor growth in both xenograft models. NOV202 was the dominant single agent in vivo, and adding olaparib resulted in a modest increase in tumor growth inhibition over NOV202 alone. Immunohistochemistry showed treatment-associated increases in DNA damage and reduced vascularization in tumors. All treatments were well tolerated with minimal signs of toxicity. In vitro, the combination induced synergistic antiproliferative effects. At the protein level, DNA-damage and apoptosis markers were increased mainly by olaparib and were not further enhanced by the combination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>NOV202 showed potent single-agent antitumor activity in both prostate cancer xenograft models. The combination with olaparib was synergistic in vitro at low nanomolar NOV202 concentrations but did not provide a clear additional benefit over NOV202 alone in vivo.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00280-026-04946-1","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T07:22:50Z","timestamp":1789629770000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Combination of PARP inhibitor olaparib and a vascular disrupting agent reduces tumor growth in a preclinical model of prostate cancer"],"prefix":"10.1007","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5947-9971","authenticated-orcid":false,"given":"Evangelia","family":"Sereti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4240-0550","authenticated-orcid":false,"given":"Susan","family":"Evans-Axelsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2192-0856","authenticated-orcid":false,"given":"Jan","family":"T\u00f6rnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9076-4597","authenticated-orcid":false,"given":"Stefan","family":"Rehnmark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2044-5598","authenticated-orcid":false,"given":"Marita","family":"H\u00f6gberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5761-3786","authenticated-orcid":false,"given":"Anders","family":"Bjartell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"issue":"3","key":"4946_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74(3):229\u2013263","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"4946_CR2","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.eururo.2018.03.028","volume":"75","author":"P Nuhn","year":"2019","unstructured":"Nuhn P et al (2019) Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology. Eur Urol 75(1):88\u201399","journal-title":"Eur Urol"},{"key":"4946_CR3","doi-asserted-by":"crossref","unstructured":"Al-Akhras A et al (2024) PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: Unraveling the Therapeutic Landscape. Life (Basel), 14(2): 198","DOI":"10.3390\/life14020198"},{"issue":"22","key":"4946_CR4","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","volume":"382","author":"J de Bono","year":"2020","unstructured":"de Bono J et al (2020) Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med 382(22):2091\u20132102","journal-title":"N Engl J Med"},{"issue":"8","key":"4946_CR5","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1056\/NEJMoa2214676","volume":"388","author":"K Fizazi","year":"2023","unstructured":"Fizazi K et al (2023) Rucaparib or Physician\u2019s Choice in Metastatic Prostate Cancer. N Engl J Med 388(8):719\u2013732","journal-title":"N Engl J Med"},{"issue":"18","key":"4946_CR6","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1200\/JCO.22.01649","volume":"41","author":"KN Chi","year":"2023","unstructured":"Chi KN et al (2023) Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol 41(18):3339\u20133351","journal-title":"J Clin Oncol"},{"issue":"26","key":"4946_CR7","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","volume":"379","author":"K Moore","year":"2018","unstructured":"Moore K et al (2018) Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med 379(26):2495\u20132505","journal-title":"N Engl J Med"},{"issue":"4","key":"4946_CR8","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1903387","volume":"381","author":"T Golan","year":"2019","unstructured":"Golan T et al (2019) Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. N Engl J Med 381(4):317\u2013327","journal-title":"N Engl J Med"},{"issue":"18","key":"4946_CR9","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1056\/NEJMc1711644","volume":"377","author":"M Robson","year":"2017","unstructured":"Robson M, Goessl C, Domchek S (2017) Olaparib for Metastatic Germline BRCA-Mutated Breast Cancer. N Engl J Med 377(18):1792\u20131793","journal-title":"N Engl J Med"},{"key":"4946_CR10","unstructured":"FDA approves olaparib for HRR gene-mutated metastatic castration-resistant prostate cancer. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer , (accessed July (2024)"},{"key":"4946_CR11","unstructured":"FDA grants accelerated approval to rucaparib for BRCA-mutated metastatic castration-resistant prostate cancer. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate , (accessed July (2024)"},{"key":"4946_CR12","unstructured":"FDA approves talazoparib with enzalutamide for HRR gene-mutated metastatic castration-resistant prostate cancer. https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate , (accessed July (2024)"},{"issue":"3","key":"4946_CR13","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.eururo.2023.05.021","volume":"84","author":"W Abida","year":"2023","unstructured":"Abida W et al (2023) Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study. Eur Urol 84(3):321\u2013330","journal-title":"Eur Urol"},{"issue":"9","key":"4946_CR14","doi-asserted-by":"publisher","first-page":"EVIDoa2200043","DOI":"10.1056\/EVIDoa2200043","volume":"1","author":"NW Clarke","year":"2022","unstructured":"Clarke NW et al (2022) Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer. NEJM Evid 1(9):EVIDoa2200043","journal-title":"NEJM Evid"},{"issue":"1","key":"4946_CR15","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41591-023-02704-x","volume":"30","author":"K Fizazi","year":"2024","unstructured":"Fizazi K et al (2024) First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nat Med 30(1):257\u2013264","journal-title":"Nat Med"},{"issue":"22","key":"4946_CR16","doi-asserted-by":"publisher","first-page":"3839","DOI":"10.1200\/JCO.23.00233","volume":"41","author":"ES Antonarakis","year":"2023","unstructured":"Antonarakis ES et al (2023) Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial. J Clin Oncol 41(22):3839\u20133850","journal-title":"J Clin Oncol"},{"issue":"10","key":"4946_CR17","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/S1470-2045(23)00382-0","volume":"24","author":"F Saad","year":"2023","unstructured":"Saad F et al (2023) Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial. Lancet Oncol 24(10):1094\u20131108","journal-title":"Lancet Oncol"},{"issue":"1","key":"4946_CR18","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.gendis.2023.02.014","volume":"11","author":"X Fu","year":"2024","unstructured":"Fu X et al (2024) Mechanism of PARP inhibitor resistance and potential overcoming strategies. Genes Dis 11(1):306\u2013320","journal-title":"Genes Dis"},{"issue":"3","key":"4946_CR19","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.eururo.2022.09.010","volume":"83","author":"A Loehr","year":"2023","unstructured":"Loehr A et al (2023) Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib. Eur Urol 83(3):200\u2013209","journal-title":"Eur Urol"},{"key":"4946_CR20","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.2147\/DDDT.S133189","volume":"11","author":"L Rickardson","year":"2017","unstructured":"Rickardson L et al (2017) Evaluation of the antitumor activity of NOV202, a novel microtubule targeting and vascular disrupting agent. Drug Des Devel Ther 11:1335\u20131351","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"4946_CR21","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ctrv.2010.05.001","volume":"37","author":"DW Siemann","year":"2011","unstructured":"Siemann DW (2011) The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents. Cancer Treat Rev 37(1):63\u201374","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"4946_CR22","doi-asserted-by":"publisher","first-page":"151075","DOI":"10.1016\/j.ejcb.2020.151075","volume":"99","author":"V \u010cerm\u00e1k","year":"2020","unstructured":"\u010cerm\u00e1k V et al (2020) Microtubule-targeting agents and their impact on cancer treatment. Eur J Cell Biol 99(4):151075","journal-title":"Eur J Cell Biol"},{"key":"4946_CR23","doi-asserted-by":"publisher","first-page":"101495","DOI":"10.1016\/j.tranon.2022.101495","volume":"24","author":"R Hellsten","year":"2022","unstructured":"Hellsten R et al (2022) The STAT3 inhibitor GPB730 enhances the sensitivity to enzalutamide in prostate cancer cells. Transl Oncol 24:101495","journal-title":"Transl Oncol"},{"key":"4946_CR24","doi-asserted-by":"crossref","unstructured":"Sereti E et al (2021) Study of the Relationship between Sigma Receptor Expression Levels and Some Common Sigma Ligand Activity in Cancer Using Human Cancer Cell Lines of the NCI-60 Cell Line Panel. Biomedicines, 9(1): 38","DOI":"10.3390\/biomedicines9010038"},{"issue":"23","key":"4946_CR25","doi-asserted-by":"publisher","first-page":"15969","DOI":"10.1074\/jbc.M114.564252","volume":"289","author":"N Don-Doncow","year":"2014","unstructured":"Don-Doncow N et al (2014) Galiellalactone Is a Direct Inhibitor of the Transcription Factor STAT3 in Prostate Cancer Cells. J Biol Chem 289(23):15969\u201315978","journal-title":"J Biol Chem"},{"issue":"1","key":"4946_CR26","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.ygyno.2020.10.005","volume":"160","author":"L Wu","year":"2021","unstructured":"Wu L et al (2021) Olaparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer and a BRCA1 and\/or BRCA2 mutation: SOLO1 China cohort. Gynecol Oncol 160(1):175\u2013181","journal-title":"Gynecol Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04946-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-026-04946-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04946-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T07:22:58Z","timestamp":1789629778000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-026-04946-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4946"],"URL":"https:\/\/doi.org\/10.1007\/s00280-026-04946-1","relation":{},"ISSN":["1432-0843"],"issn-type":[{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]},"assertion":[{"value":"26 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following financial interests\/personal relationships which may be considered as potential competing interests: Stefan Rehnmark, Marita H\u00f6gberg, Jan T\u00f6rnell and Anders Bjartell are shareholders in LIDDS AB. Material support for this research and\/or work are clearly identified in the manuscript. NOV202 was provided by LIDDS AB. The company had no influence on the performance or reporting of this study. The authors report no other conflicts of interest related to this work.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"102"}}